Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer

Trial Profile

Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs GM 102 (Primary)
  • Indications Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer
  • Focus Adverse reactions; First in man
  • Sponsors GamaMabs Pharma
  • Most Recent Events

    • 05 Jun 2018 Results (n=27) assessing safety, pharmacokinetics and pharmacodynamics presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 22 May 2018 Results from monotherapy treatment arm (n=27) presented in a GamaMabs Pharma media release.
    • 12 Apr 2018 According to a GamaMabs media release, inital results from this study will be presented at the 2018 ASCO annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top